Together, these results suggest that CCT2 in breast cancer cells-derived exosomes modulate CD4+ T cells activation through the Ca2+-NFAT1 pathway, ultimately compromising antitumor immunity. This evidence concerns the gene CCT2 and breast carcinoma.